1543 related articles for article (PubMed ID: 10778950)
41. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
42. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
43. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma.
Wos E; Olencki T; Tuason L; Budd GT; Peereboom D; Sandstrom K; McLain D; Finke J; Bukowski RM
Cancer; 1996 Mar; 77(6):1149-53. PubMed ID: 8635137
[TBL] [Abstract][Full Text] [Related]
45. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
[TBL] [Abstract][Full Text] [Related]
46. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
[TBL] [Abstract][Full Text] [Related]
47. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
49. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
50. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
51. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
53. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
54. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
55. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
[TBL] [Abstract][Full Text] [Related]
56. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
57. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
58. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
59. Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial.
Veelken H; Rosenthal FM; Schneller F; von Schilling C; Guettler IC; Herrmann F; Mertelsmann R; Lindemann A
Biotechnol Ther; 1992; 3(1-2):1-14. PubMed ID: 1305889
[TBL] [Abstract][Full Text] [Related]
60. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
